M. Bolhuis, T. Van-der-laan, J. Kosterink, T. Van-der-werf, D. Van-soolingen et al., In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis, European Respiratory Journal, vol.44, issue.3, pp.808-819, 2014.
DOI : 10.1183/09031936.00041314
URL : http://erj.ersjournals.com/content/erj/44/3/808.full.pdf

S. Brown and M. Traczewski, Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges, Antimicrobial Agents and Chemotherapy, vol.54, issue.5, pp.2063-2072, 2010.
DOI : 10.1128/AAC.01569-09

B. Brown-elliott and R. Wallace, Clinical and Taxonomic Status of Pathogenic Nonpigmented or Late-Pigmenting Rapidly Growing Mycobacteria, Clinical Microbiology Reviews, vol.15, issue.4, pp.716-762, 2002.
DOI : 10.1128/CMR.15.4.716-746.2002
URL : http://cmr.asm.org/content/15/4/716.full.pdf

B. Brown-elliott and R. Wallace, ABSTRACT, Journal of Clinical Microbiology, vol.55, issue.6, pp.1747-54, 2017.
DOI : 10.1128/JCM.00274-17

J. Bryant, D. Grogono, D. Rodriguez-rincon, I. Everall, K. Brown et al., Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium, Science, vol.40, issue.6313, pp.751-758, 2016.
DOI : 10.1128/jb.179.11.3783-3785.1997
URL : http://europepmc.org/articles/pmc5142603?pdf=render

C. Wayne and P. , Susceptibility testing of mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standard. CLSI, pp.24-26, 2011.

R. Cremades, A. Santos, J. Rodríguez, E. Garcia-pachón, M. Ruiz et al., Mycobacterium abscessus from respiratory isolates: activities of drug combinations, Journal of Infection and Chemotherapy, vol.15, issue.1, pp.46-54, 2009.
DOI : 10.1007/s10156-008-0651-Y

A. Dacosta, C. Jordan, O. Giddings, F. Lin, P. Gilligan et al., Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients, Journal of Cystic Fibrosis, vol.16, issue.4, pp.483-490, 2017.
DOI : 10.1016/j.jcf.2017.04.013

K. Dheda, T. Gumbo, G. Maartens, K. Dooley, R. Mcnerney et al., The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis, The Lancet Respiratory Medicine, vol.5, issue.4, pp.291-360, 2017.
DOI : 10.1016/S2213-2600(17)30079-6
URL : http://researchonline.lshtm.ac.uk/3716724/1/The%20epidemiology%2C%20pathogenesis%2C%20transmission%2C%20diagnosis%2C%20and%20management%20of%20multidrug-resistant%2C%20extensively%20drug-resistant.pdf

G. Drusano, W. Liu, R. Kulawy, and A. Louie, ABSTRACT, Antimicrobial Agents and Chemotherapy, vol.55, issue.11, pp.5300-5305, 2011.
DOI : 10.1128/AAC.00502-11

S. Flanagan, P. Bien, K. Muñoz, S. Minassian, and P. Prokocimer, Pharmacokinetics of Tedizolid Following Oral Administration: Single and Multiple Dose, Effect of Food, and Comparison of Two Solid Forms of the Prodrug, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.35, issue.Suppl 4, pp.240-50, 2014.
DOI : 10.1124/dmd.106.013755

T. Gonzalez-santiago and L. Drage, Nontuberculous Mycobacteria, Dermatologic Clinics, vol.33, issue.3, pp.563-77, 2015.
DOI : 10.1016/j.det.2015.03.017

D. Griffith, T. Aksamit, B. Brown-elliott, A. Catanzaro, C. Daley et al., An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases, American Journal of Respiratory and Critical Care Medicine, vol.175, issue.4, pp.367-416, 2007.
DOI : 10.1016/S0140-6736(01)05843-3

L. Khatchatourian, L. Bourgeois, A. Asseray, N. Biron, C. Lefebvre et al., Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments, Journal of Antimicrobial Chemotherapy, vol.71, issue.7, pp.2135-2141, 2017.
DOI : 10.1093/jac/dkw206

M. Lee, J. Lee, M. Carroll, H. Choi, M. S. Song et al., Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis, New England Journal of Medicine, vol.367, issue.16, pp.1508-1526, 2012.
DOI : 10.1056/NEJMoa1201964
URL : http://europepmc.org/articles/pmc3814175?pdf=render

A. Lefebvre, V. Dubée, M. Cortes, D. Dorchêne, M. Arthur et al., Journal of Antimicrobial Chemotherapy, vol.71, issue.6, pp.1556-63, 2016.
DOI : 10.1093/infdis/jit614

S. Lemaire, F. Van-bambeke, P. Appelbaum, and P. Tulkens, Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines, Journal of Antimicrobial Chemotherapy, vol.50, issue.2, pp.1035-1078, 2009.
DOI : 10.1128/AAC.50.2.765-769.2006
URL : https://academic.oup.com/jac/article-pdf/64/5/1035/2112004/dkp267.pdf

T. Lodise, M. Bidell, S. Flanagan, E. Zasowski, S. Minassian et al., Characterization of the haematological profile of 21 days of tedizolid in healthy subjects, Journal of Antimicrobial Chemotherapy, vol.34, issue.9, pp.2553-2561, 2016.
DOI : 10.1128/AAC.01185-10

E. Macheras, A. Roux, S. Bastian, S. Leão, M. Palaci et al., Multilocus Sequence Analysis and rpoB Sequencing of Mycobacterium abscessus (Sensu Lato) Strains, Journal of Clinical Microbiology, vol.49, issue.2, pp.491-500, 2011.
DOI : 10.1128/JCM.01274-10
URL : https://jcm.asm.org/content/49/2/491.full.pdf

F. Maurer, V. Bruderer, C. Ritter, C. Castelberg, G. Bloemberg et al., ABSTRACT, Antimicrobial Agents and Chemotherapy, vol.58, issue.7, pp.3828-3864, 2014.
DOI : 10.1128/AAC.02448-14

C. Molina-torres, A. Barba-marines, O. Valles-guerra, J. Ocampo-candiani, N. Cavazos-rocha et al., Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages, Annals of Clinical Microbiology and Antimicrobials, vol.13, issue.1, p.13, 2014.
DOI : 10.1016/S0168-3659(00)00339-4
URL : https://ann-clinmicrob.biomedcentral.com/track/pdf/10.1186/1476-0711-13-13?site=ann-clinmicrob.biomedcentral.com

F. Mougari, L. Guglielmetti, L. Raskine, I. Sermet-gaudelus, N. Veziris et al., : epidemiology, diagnostic tools and treatment, Expert Review of Anti-infective Therapy, vol.77, issue.3, pp.1139-54, 2016.
DOI : 10.1097/QCO.0000000000000104

S. Oh, J. Kim, S. Baek, C. S. Park, H. Cho et al., In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria, Molecules, vol.61, issue.3, 2017.
DOI : 10.2217/14750708.3.4.521

T. Qvist, M. Gilljam, B. Jönsson, D. Taylor-robinson, S. Jensen-fangel et al., Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia, Journal of Cystic Fibrosis, vol.14, issue.1, pp.46-52, 2015.
DOI : 10.1016/j.jcf.2014.08.002
URL : https://doi.org/10.1016/j.jcf.2014.08.002

M. Sahre, S. Sabarinath, M. Grant, C. Seubert, C. Deanda et al., Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers, International Journal of Antimicrobial Agents, vol.40, issue.1, pp.51-55, 2012.
DOI : 10.1016/j.ijantimicag.2012.03.006

R. Schaadt, D. Sweeney, D. Shinabarger, and G. Zurenko, In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent, Antimicrobial Agents and Chemotherapy, vol.53, issue.8, pp.3236-3245, 2009.
DOI : 10.1128/AAC.00228-09

M. Schlosser, H. Hosako, A. Radovsky, M. Butt, D. Draganov et al., ABSTRACT, Antimicrobial Agents and Chemotherapy, vol.18, issue.1, pp.475-81, 2015.
DOI : 10.1345/aph.1C361

K. Shaw, S. Poppe, R. Schaadt, V. Brown-driver, J. Finn et al., In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains, Antimicrobial Agents and Chemotherapy, vol.52, issue.12, pp.4442-4449, 2008.
DOI : 10.1128/AAC.00859-08

R. Tasneen, F. Betoudji, S. Tyagi, S. Li, K. Williams et al., ABSTRACT, Antimicrobial Agents and Chemotherapy, vol.60, issue.1, pp.270-277, 2015.
DOI : 10.1128/AAC.01691-15

L. Vera-cabrera, B. Brown-elliott, R. Wallace, J. Ocampo-candiani, O. Welsh et al., In Vitro Activities of the Novel Oxazolidinones DA-7867 and DA-7157 against Rapidly and Slowly Growing Mycobacteria, Antimicrobial Agents and Chemotherapy, vol.50, issue.12, pp.4027-4036, 2006.
DOI : 10.1128/AAC.00763-06
URL : http://aac.asm.org/content/50/12/4027.full.pdf

F. Wagenlehner, S. Wydra, H. Onda, M. Kinzig-schippers, F. Sörgel et al., Concentrations in Plasma, Urinary Excretion, and Bactericidal Activity of Linezolid (600 Milligrams) versus Those of Ciprofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose, Antimicrobial Agents and Chemotherapy, vol.47, issue.12, pp.3789-94, 2003.
DOI : 10.1128/AAC.47.12.3789-3794.2003

J. Yuste, J. Bertó, D. Pozo, J. Leiva, and J. , Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity, Journal of Antimicrobial Chemotherapy, vol.72, issue.2, pp.625-633, 2017.
DOI : 10.1128/AAC.03431-14

M. Zhang, C. Sala, N. Dhar, A. Vocat, V. Sambandamurthy et al., ABSTRACT, Antimicrobial Agents and Chemotherapy, vol.58, issue.6, pp.3217-3240, 2014.
DOI : 10.1128/AAC.02410-14
URL : https://hal.archives-ouvertes.fr/hal-01126336

Z. Zhang, J. Lu, M. Liu, Y. Wang, Y. Zhao et al., In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense, International Journal of Antimicrobial Agents, vol.49, issue.3, pp.383-389, 2017.
DOI : 10.1016/j.ijantimicag.2016.12.003

W. Zhao, M. Zheng, B. Wang, X. Mu, P. Li et al., Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo, International Journal of Infectious Diseases, vol.52, pp.23-31, 2016.
DOI : 10.1016/j.ijid.2016.08.027

L. Zou, M. Liu, Y. Wang, J. Lu, and Y. Pang, Determination of in??vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates, Tuberculosis, vol.95, issue.6, pp.839-881, 2015.
DOI : 10.1016/j.tube.2015.07.003